Ask AI
ProCE Banner Activity

ARTISTRY-2: Phase III Trial of Single-Tablet BIC/LEN Switch vs BIC/FTC/TAF Continuation in People With HIV and Virologic Suppression

Conference Coverage
Slideset

The phase III ARTISTRY-2 trial demonstrated that switching to single-tablet bictegravir/lenacapavir was noninferior to continuing bictegravir/emtricitabine/tenofovir alafenamide in maintaining virologic suppression in people with HIV at 48 weeks.

Released: February 26, 2026

Continue Activity

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by independent educational grants from Gilead Sciences, Inc., Merck & Co., Inc., Rahway, NJ, USA, and ViiV Healthcare.

Gilead Sciences, Inc.

Merck & Co., Inc., Rahway, NJ, USA

ViiV Healthcare

Target Audience

This activity is intended for physicians, pharmacists, registered nurses, and other healthcare professionals who care for people living with or at risk of HIV infection.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Appropriately apply and counsel patients regarding the clinical role(s) of new and investigational ART regimens and strategies

  • Devise HIV management strategies based on the results of recent clinical studies of established antiretroviral agents

  • Integrate the latest scientific findings to develop and optimize effective HIV prevention interventions